Shockwave Medical and CRISPR Therapeutics Beat Expectations in Q1 Earnings, Ocular Therapeutix Falls Short
- May 08th, 2023
- 481 views
Shockwave Medical, Inc. (Nasdaq: SWAV) reported better-than-expected Q1 earnings, with an EPS of $1.03 versus the consensus estimate of $0.81. In after-hours trading, SWAV is up $10.04 (+3.65%) and is currently trading at $285.00.
On the other hand, CRISPR Therapeutics AG (Nasdaq: CRSP) reported a Q1 loss of $0.67 per share, which was better than the consensus estimate of a loss of $1.70 per share. As a result, in after-hours trading, CRSP is up $0.54 (+0.96%) and is currently trading at $56.50.
Finally, Ocular Therapeutix, Inc. (Nasdaq: OCUL) reported a Q1 loss of $0.39 per share, worse than the consensus estimate of a loss of $0.26 per share. As a result, in after-hours trading, OCUL is down $0.30 (-4.69%) and is currently trading at $6.10.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login